{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:18:31Z","timestamp":1783383511704,"version":"3.54.6"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370535"],"award-info":[{"award-number":["82370535"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Crohn\u2019s disease (CD) patients exhibit changed body composition, with elevated visceral adipose tissue (VAT) and reduced skeletal muscle (SM). This study aimed to investigate the impact of VAT and SM on the efficacy of CD biologics and develop a predictive model for loss of response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicenter retrospective cohort study. CD patients initially treated with infliximab and ustekinumab were enrolled between January 2018 and December 2023. The visceral fat index (VFI) and skeletal muscle index (SMI) were measured using computed tomography. Patients were divided into 3 groups based on tertiles of VFI (quartile 1 [Q1]: &amp;lt;0.575; Q2: 0.575-0.885; Q3: \u22650.885) and SMI (Q1: &amp;lt;36.4; Q2: 36.4-44.4; Q3: \u226544.4). The primary outcome was loss of response at 52\u2009weeks and the secondary outcome was primary nonresponse after induction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 248 patients were included. The lowest SMI group had higher rates of primary nonresponse (Q1 vs Q2 vs Q3: 15.7% vs 7.2% vs 3.7%; P\u2009=\u2009.021) and loss of response (Q1 vs Q2 vs Q3: 38.0% vs 17.1% vs 16.5%; P\u2009&amp;lt;\u2009.001). Higher VFI was linked with increased loss of response (Q1 vs Q2 vs Q3: 12.8% vs 17.1% vs 41.7%; P\u2009&amp;lt;\u2009.001) and lower mucosal healing rates (Q1 vs Q2 vs Q3: 63.9% vs 40.0% vs 26.9%; P\u2009&amp;lt;\u2009.001). Elevated VFI (male\u2009&amp;gt;0.887, female\u2009&amp;gt;0.679) and reduced SMI (male\u2009&amp;lt;40.2, female\u2009&amp;lt;31.0) were independent risk factors for 52-week loss of response. A predictive model combining body composition parameters and clinical data showed strong performance, with an externally validated area under the curve of area under the curve of 0.902 (95% confidence interval, 0.828-0.975).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated VAT and reduced SM were associated with loss of response in CD biologics. The predictive model integrating body composition parameters demonstrated good performance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag023","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:30:45Z","timestamp":1769430645000},"page":"1268-1278","source":"Crossref","is-referenced-by-count":0,"title":["Impact of visceral adipose tissue and skeletal muscle on early and long-term biologic treatment failure in Crohn\u2019s disease: A multicenter retrospective cohort study"],"prefix":"10.1093","volume":"32","author":[{"given":"Qiong","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University , Nanjing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanrongzi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital with Nanjing Medical University , Nanjing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Northern Jiangsu People\u2019s Hospital Affiliated to Yangzhou University , Yangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijiao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital of Soochow University , Suzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University , Nanjing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University , Nanjing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University , Nanjing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University , Nanjing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4497-0503","authenticated-orcid":false,"given":"Hongjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University , Nanjing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"2026070620122983300_izag023-B1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2026070620122983300_izag023-B2","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"Therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026070620122983300_izag023-B3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070620122983300_izag023-B4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/nu13020656","article-title":"Sarcopenia in inflammatory bowel disease: a narrative overview","volume":"13","author":"Dhaliwal","year":"2021","journal-title":"Nutrients"},{"key":"2026070620122983300_izag023-B5","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3390\/biom9120780","article-title":"Role of obesity, mesenteric adipose tissue, and adipokines in inflammatory bowel diseases","volume":"9","author":"Bilski","year":"2019","journal-title":"Biomolecules"},{"key":"2026070620122983300_izag023-B6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2023.06.036","article-title":"Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases initiating biologic therapy: results of the constellation study","volume":"165","author":"Yarur","year":"2023","journal-title":"Gastroenterology"},{"key":"2026070620122983300_izag023-B7","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1097\/cm9.0000000000003222","article-title":"2023 Chinese national clinical practice guideline on diagnosis and management of Crohn\u2019s disease","volume":"137","author":"Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association; Inflammatory Bowel Disease Quality Control Center of China","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"2026070620122983300_izag023-B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3945\/ajcn.115.111203","article-title":"What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults?","volume":"102","author":"Schweitzer","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"2026070620122983300_izag023-B9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jcsm.12158","article-title":"A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients","volume":"8","author":"van Vugt","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026070620122983300_izag023-B10","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.3390\/jcm12144713","article-title":"Diagnostic criteria and prognostic relevance of sarcopenia in patients with inflammatory bowel disease-a systematic review","volume":"12","author":"Potcovaru","year":"2023","journal-title":"J Clin Med"},{"key":"2026070620122983300_izag023-B11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/1751-2980.12994","article-title":"Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing)","volume":"22","author":"Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association","year":"2021","journal-title":"J Dig Dis"},{"key":"2026070620122983300_izag023-B12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070620122983300_izag023-B13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/apt.15784","article-title":"Effectiveness of ustekinumab dose escalation in Crohn\u2019s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy","volume":"52","author":"Kopylov","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620122983300_izag023-B14","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/ibd\/izad184","article-title":"Efficacy of ustekinumab optimization by 2 initial intravenous doses in adult patients with severe Crohn\u2019s disease","volume":"30","author":"Ren","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620122983300_izag023-B15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1053\/j.gastro.2023.09.029","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of Crohn\u2019s disease","volume":"165","author":"Ananthakrishnan","year":"2023","journal-title":"Gastroenterology"},{"key":"2026070620122983300_izag023-B16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/jama.1984.03340250053024","article-title":"A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer","volume":"251","author":"Crohn","year":"1984","journal-title":"JAMA"},{"key":"2026070620122983300_izag023-B17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/cells8060628","article-title":"The role of adipose tissue in the pathogenesis and therapeutic outcomes of inflammatory bowel disease","volume":"8","author":"Eder","year":"2019","journal-title":"Cells"},{"key":"2026070620122983300_izag023-B18","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1097\/MIB.0000000000000527","article-title":"Visceral adipose tissue in patients with Crohn\u2019s disease correlates with disease activity, inflammatory markers, and outcome","volume":"21","author":"B\u00fcning","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620122983300_izag023-B19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/MIB.0000000000000978","article-title":"Visceral adiposity, genetic susceptibility, and risk of complications among individuals with Crohn\u2019s disease","volume":"23","author":"Van Der Sloot","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620122983300_izag023-B20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/ibd\/izab167","article-title":"Visceral adipose tissue volumetrics inform odds of treatment response and risk of subsequent surgery in IBD patients starting antitumor necrosis factor therapy","volume":"28","author":"Gu","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620122983300_izag023-B21","doi-asserted-by":"publisher","first-page":"e00233","DOI":"10.14309\/ctg.0000000000000233","article-title":"The effect of adiposity on anti-tumor necrosis factor-alpha levels and loss of response in Crohn\u2019s disease patients","volume":"11","author":"Lim","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"2026070620122983300_izag023-B22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2026070620122983300_izag023-B23","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.14309\/ajg.0000000000002330","article-title":"Patients with inflammatory bowel diseases and higher visceral adipose tissue burden may benefit from higher infliximab concentrations to achieve remission","volume":"118","author":"Yarur","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026070620122983300_izag023-B24","doi-asserted-by":"publisher","first-page":"116116","DOI":"10.1016\/j.bcp.2024.116116","article-title":"The pathophysiology of visceral adipose tissues in cardiometabolic diseases","volume":"222","author":"Lee","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"2026070620122983300_izag023-B25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/cpt.2969","article-title":"Mechanistic, functional, and clinical aspects of proinflammatory cytokine mediated regulation of ADME gene expression in 3D human liver spheroids","volume":"114","author":"Kl\u00f6ditz","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2026070620122983300_izag023-B26","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/apt.17498","article-title":"Review article: putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease","volume":"57","author":"Gold","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620122983300_izag023-B27","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.clnu.2023.05.002","article-title":"Systematic review of sarcopenia in inflammatory bowel disease","volume":"42","author":"Fatani","year":"2023","journal-title":"Clin Nutr"},{"key":"2026070620122983300_izag023-B28","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/MIB.0000000000001166","article-title":"Sarcopenia is a predictor of surgical morbidity in inflammatory bowel disease","volume":"23","author":"Pedersen","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620122983300_izag023-B29","doi-asserted-by":"publisher","first-page":"111526","DOI":"10.1016\/j.nut.2021.111526","article-title":"Sarcopenia hinders the decline in disease activity after surgery for people with Crohn\u2019s disease: preliminary results","volume":"94","author":"Yasueda","year":"2022","journal-title":"Nutrition"},{"key":"2026070620122983300_izag023-B30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/apt.14293","article-title":"The body composition profile is associated with response to anti-TNF therapy in Crohn\u2019s disease and may offer an alternative dosing paradigm","volume":"46","author":"Ding","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620122983300_izag023-B31","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1111\/cts.13621","article-title":"Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn\u2019s disease","volume":"16","author":"Liu","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2026070620122983300_izag023-B32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nrrheum.2014.193","article-title":"Exercise as an anti-inflammatory therapy for rheumatic diseases-myokine regulation","volume":"11","author":"Benatti","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2026070620122983300_izag023-B33","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/DCR.0000000000001074","article-title":"Visceral fat is associated with mucosal healing of infliximab treatment in Crohn\u2019s disease","volume":"61","author":"Shen","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"2026070620122983300_izag023-B34","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cell.2020.09.009","article-title":"Translocation of viable gut microbiota to mesenteric adipose drives formation of creeping fat in humans","volume":"183","author":"Ha","year":"2020","journal-title":"Cell"},{"key":"2026070620122983300_izag023-B35","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/ecco-jcc\/jjab159","article-title":"The complex relationship between microbiota, immune response and creeping fat in Crohn\u2019s disease","volume":"16","author":"Suau","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026070620122983300_izag023-B36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/apt.13058","article-title":"Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn\u2019s disease","volume":"41","author":"Subramaniam","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620122983300_izag023-B37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1590\/1806-9282.63.05.407","article-title":"Impact of biological therapy on body composition of patients with Chron\u2019s disease","volume":"63","author":"Santos","year":"2017","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"2026070620122983300_izag023-B38","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/nu15153479","article-title":"Evaluation of albumin, transferrin and transthyretin in inflammatory bowel disease patients as disease activity and nutritional status biomarkers","volume":"15","author":"Godala","year":"2023","journal-title":"Nutrients"},{"key":"2026070620122983300_izag023-B39","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1097\/MEG.0000000000001493","article-title":"Serum\u03b3-globulin and albumin concentrations predict secondary loss of response to anti-TNF\u03b1 in inflammatory bowel disease patients","volume":"31","author":"Schoenefuss","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026070620122983300_izag023-B40","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1097\/MIB.0000000000000475","article-title":"Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response to treatment for Crohn\u2019s disease: a prospective clinical trial","volume":"21","author":"Suzuki","year":"2015","journal-title":"Inflamm Bowel Dis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/7\/1268\/67370524\/izag023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/7\/1268\/67370524\/izag023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:12:40Z","timestamp":1783383160000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/7\/1268\/8524938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag023","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,16]]}}}